Money, Data & Research
GiveWell aims to grant at least $2.5 billion for malaria from 2027 through 2032
The charity evaluator says the target could grow several times over as Global Fund and Gavi budgets shrink, but much depends on a partnership not yet approved.
By The Editors · The Game of Giving
GiveWell, the charity evaluator that directs donors' money to programs it judges most cost-effective, aims to grant at least $2.5 billion in new malaria funding from 2027 through 2032, it said on October 26. The post says the total could be "several times" that.
GiveWell is a nonprofit that researches charities and recommends where donations can do the most good per dollar. It says it has directed more than $1.3 billion to malaria prevention and treatment over its history, including more than $750 million for insecticide-treated nets and more than $500 million for seasonal malaria chemoprevention, the practice of giving children preventive drugs during the rainy season. It estimates that spending will save more than 300,000 lives.
Why is GiveWell scaling up now?
GiveWell points to falling donor money for the biggest malaria funders. The post says Global Fund donors pledged $12.6 billion for its latest three-year cycle, down from $15.7 billion three years earlier and short of an $18 billion target. The Global Fund confirmed a final total of $12.64 billion in February.
According to GiveWell, the Global Fund then allocated $3.5 billion to countries for its next three years of malaria grants, about 15% less than the previous cycle, and Gavi, the vaccine alliance, raised just under $10 billion of an $11.9 billion budget for 2026-2030 and cut the malaria vaccine coverage it will fund. Malaria kills around 600,000 people a year, most of them young children. "We know how to prevent, diagnose, and treat malaria," the post says.
How big is $2.5 billion next to other malaria money?
At the minimum target, it would be roughly $417 million a year. The comparison below is our own arithmetic from the figures GiveWell and the Global Fund published.
| Funding figure | Amount | Per year (our arithmetic) |
|---|---|---|
| GiveWell malaria target, 2027-2032 (minimum) | $2.5 billion over 6 years | About $417 million |
| Global Fund malaria allocations, next 3 years | $3.5 billion | About $1.17 billion |
| GiveWell total grants committed in 2025, all areas | $418 million | One year |
| GiveWell malaria funding to date | More than $1.3 billion | Its full history |
By that measure, GiveWell's floor alone would equal about a third of the Global Fund's yearly malaria allocation. GiveWell also says it expects to grant more than $1 billion in total this year, more than double 2025.
Where would the money go?
GiveWell lists nets, chemoprevention and malaria vaccines for prevention, plus testing and treatment by community health workers and supply chains. It may also fund newer tools, such as spatial emanators and insecticide-treated babywraps, if the evidence supports them. Initial grants would cover about two to three years of programs, with renewals planned.
One route is a proposed Malaria Impact Accelerator with the Global Fund, which the Global Fund's board has not yet approved. GiveWell is also exploring a partnership with Gavi on malaria vaccines. It says the total will depend on its own funding, country demand and how malaria compares with its other priorities.
What should donors and nonprofits watch?
The plan is a target, not a committed gift, and GiveWell lists its own risks: the Global Fund partnership could shrink or not happen, countries may want less than expected, and larger private funding could lead governments to cut their own malaria budgets. In our view, the post is a useful model of saying out loud what could go wrong before the money moves. GiveWell judges programs by cost-effectiveness, a different yardstick from the overhead ratio, which we have argued tells donors less than they think. U.S. donors are already sending large sums abroad through intermediaries, as a Council on Foundations report on donor-advised funds found.
General information for donors and nonprofit leaders, not legal or tax advice. How we report is set out in our editorial guide.
